Contact | Print version | PDF version | Send article | RSS feed

Amorfix Life Sciences in-licenses second novel technology to strengthen its ALS therapeutic program

07 Apr 2006 - Amorfix Life Sciences Ltd. reported today that it has obtained the exclusive worldwide rights to additional novel targets on Superoxide Dismutase-1 (SOD1), which is a protein known to misfold and aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS). These new SOD1 targets broaden Amorfix's intellectual property estate on SOD1 and enhance its existing diagnostic and therapeutic strategies for the treatment of ALS. The company also obtained an option to acquire the intellectual property and know how surrounding the licensed technology.
 
The novel SOD1 targets were discovered by Dr. Avi Chakrabarrty and Mr. Rishi Rakhit at the University Health Network (UHN) and Dr. Neil Cashman, the company's Chief Scientific Officer, in his former academic laboratory at the University of Toronto. Dr. Cashman has assigned his portion of the technology rights to Amorfix. The company has licensed the remaining rights from UHN and has committed to invest a minimum of $260,000 on development of the technology at UHN.